Phase II Study With Cabozantinib in Patients With RET Positive NSCLC
Status:
Recruiting
Trial end date:
2022-08-07
Target enrollment:
Participant gender:
Summary
This study is aimed to explore the antitumor activity, safety and efficacy profile of
cabozantinib in pretreated, advanced RET-rearranged non-small cell lung cancer patients
Phase:
Phase 2
Details
Lead Sponsor:
University of Bologna
Collaborators:
AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology Bioikos Ambiente Srl Ipsen Mipharm SpA